1-methoxybicyclo<2.2.2>octan-2-one | 53921-93-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-methoxybicyclo<2.2.2>octan-2-one
• 英文别名: 1-methoxybicyclo[2.2.2]octan-2-one
• CAS: 53921-93-0
• 化学式: C₉H₁₄O₂
• 分子量: 154.209
• InChiKey: DDWYWFBBYPOQTH-UHFFFAOYSA-N

物化性质

• 沸点：
  224.3±23.0 °C(Predicted)
• 密度：
  1.06±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-methoxybicyclo<2.2.2>octan-2-one 在 吡啶 、 2,6-二甲基吡啶 、 碘代三甲硅烷 、 四丁基氟化铵 、 sodium hydride 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 108.0h， 生成 1-Ethoxy-(E)-2-ethylidenebicyclo<2.2.2>octane
  参考文献：
  名称：

  Solvolysis of 2-methylene bicyclic bridgehead derivatives: a model for gradual variation of .pi.-conjugation in carbocations

  摘要：

  The rates of solvolysis in ethanol or 80% ethanol at 25-degrees-C have been determined on 2-methylenebicyclo[2.2.2]oct-1-yl triflate (4a), 2-methylenebicyclo[3.2.1]oct-1-yl triflate (5a), 2-methylenebicyclo[3.2.2]non-1-yl mesylate (6a), 2-methylenebicyclo[3.3.1]non-1-yl mesylate (7a-OMs) and heptafluorobutyrate (7a-OHFB), 1-chloro-2-methylenebicyclo[4.2.2]decane (8a), 2-methylenebicyclo[4.3.1]dec-1-yl trifluoroacetate (9a), and 4-methylene-3-homoadamantyl heptafluorobutyrate (10a) and on their corresponding parent 1-bicycloalkyl and 3-homoadamantyl derivatives 4b-10b containing the respective leaving group. The rate ratios for 4a/4b, 5a/5b, 10a/10b, 6a/6b, 7a/7b, 8a/8b, and 9a/9b are 10(-3.9), 10(-1.9), 10(-1.1), 10(0.8), 10(0.9) (for mesylate), 10(-0.2), and 10(0.7), respectively. A plot of the logarithms of the rate ratios against olefinic strain energies of their corresponding unsubstituted bridgehead olefins shows that the smaller the olefinic strain energy, the greater the rate ratio, providing a methodology to gradually change the conjugative ability of bridgehead carbocations. The enhancement of allylic conjugation with increasing skeletal flexibility has been further verified by the enhanced solvolysis rate of (E)-2-ethylidenebicyclo[3.2.2]non-1-yl mesylate ((E)-6e) relative to 6a by a factor of 259. A similar study on much more rigid (E)-2-ethylidenebicyclo[2.2.2]oct-1-yl triflate ((E)-4e) gave a (E)-4e/4a rate ratio of 6.3. AM1 semiempirical molecular orbital calculations on pertinent 2-methylene and (E)-2-ethylidene bridgehead carbocations and corresponding hydrocarbons (L = hydrogen) also supported the increase in the conjugation with increasing skeletal flexibility. The solvolysis products were solely bridgehead substitution products, no indication for the formation of bridgehead olefin via an S(N)1' mechanism having been obtained.

  DOI：

  10.1021/jo00027a050
• 作为产物：
  描述：

  1-methoxybicyclo[2.2.2]oct-5-en-2-one 在 镍 氢气 作用下， 以 甲醇 为溶剂， 40.0 ℃ 、41.37 MPa 条件下， 反应 3.0h， 以to produce 1-methoxybicyclo[2.2.2]octan-2-one (15.0 g, 90%)的产率得到1-methoxybicyclo<2.2.2>octan-2-one
  参考文献：
  名称：

  Aspartic Protease Inhibitors

  摘要：

  本发明涉及天冬氨酸蛋白酶抑制剂。本发明所述的某些天冬氨酸蛋白酶抑制剂可以用以下结构式或其药学上可接受的盐来表示。本发明还涉及包括所述天冬氨酸蛋白酶抑制剂的药物组合物。本发明还涉及在需要拮抗一种或多种天冬氨酸蛋白酶的主体中的方法，以及使用所述天冬氨酸蛋白酶抑制剂治疗天冬氨酸蛋白酶介导的疾病的方法。

  公开号：

  US20100048636A1

文献信息

• Aspartic Protease Inhibitors
  申请人：Baldwin John J.

  公开号：US20100048636A1

  公开（公告）日：2010-02-25

  The present invention is directed to aspartic protease inhibitors. Certain aspartic protease inhibitors of the invention can be represented by the following structural formula or a pharmaceutically acceptable salt thereof. The present invention is also directed to pharmaceutical compositions comprising the disclosed aspartic protease inhibitors. The present invention is further directed to methods of antagonizing one or more aspartic proteases in a subject in need thereof, and methods for treating an aspartic protease mediated disorder in a subject using the disclosed aspartic protease inhibitors.

  本发明涉及天冬氨酸蛋白酶抑制剂。本发明所述的某些天冬氨酸蛋白酶抑制剂可以用以下结构式或其药学上可接受的盐来表示。本发明还涉及包括所述天冬氨酸蛋白酶抑制剂的药物组合物。本发明还涉及在需要拮抗一种或多种天冬氨酸蛋白酶的主体中的方法，以及使用所述天冬氨酸蛋白酶抑制剂治疗天冬氨酸蛋白酶介导的疾病的方法。
• NOVEL PYRIDAZINE DERIVATIVES
  申请人：Trah Stephan

  公开号：US20100113464A1

  公开（公告）日：2010-05-06

  The present invention relates to novel pyridazine derivatives of formula I as active ingredients which have microbiocidal activity, in particular fungicidal activity: wherein R 1 is hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl or C 3 -C 6 cycloalkyl; R 2 is an optionally substituted heteroaryl; R 3 is an optionally substituted aryl; and R 4 is hydrogen, halogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, (VCehaloalkoxy, hydroxy or cyano; or an agrochemically usable salt form thereof.

  本发明涉及一种新的吡嗪衍生物，其化学式为I，作为活性成分具有微生物杀菌活性，特别是真菌杀菌活性：其中R1为氢，C1-C6烷基，C1-C6卤代烷基或C3-C6环烷基；R2为可选取代的杂环芳基；R3为可选取代的芳基；R4为氢，卤素，C1-C6烷基，C1-C6卤代烷基，C1-C6烷氧基，(VCe卤代烷氧基，羟基或氰基；或其农药可用盐形式。
• [EN] CYCLIC COMPOUNDS AND METHODS OF USING SAME<br/>[FR] COMPOSÉS CYCLIQUES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：SCHROEDINGER INC

  公开号：WO2022197898A1

  公开（公告）日：2022-09-22

  The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof. The present application also describes pharmaceutical composition comprising a compound of Formula (I), and pharmaceutically acceptable salts thereof, and methods of using the compounds and compositions for inhibiting kinase activity, and for treating cancer.

  本申请涉及公式（I）所定义的化合物及其药学上可接受的盐。本申请还描述了包含公式（I）化合物及其药学上可接受的盐的药物组合物，以及使用这些化合物和组合物抑制激酶活性和治疗癌症的方法。
• ASPARTIC PROTEASE INHIBITORS
  申请人：Vitae Pharmaceuticals, Inc.

  公开号：EP1966139B1

  公开（公告）日：2011-12-21
• US8487108B2
  申请人：——

  公开号：US8487108B2

  公开（公告）日：2013-07-16